Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and polynucleotides, and methods of use thereof.

Abstract: The present disclosure provides alternative sugar moieties and polynucleotides comprising such sugar moieties, and methods of use thereof.

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of chimeric polynucleotide molecules.

Abstract: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.

Abstract: The present invention relates to dideoxynucleoside analog compounds containing a dideoxy ribofuranosyl moiety that exhibit selective anti-viral activity coupled with substantially low toxicity toward the host cells. In particular, the compounds according to the present invention show potent inhibition of the replication of the human immunodeficiency virus (HIV), while remaining substantially inert toward host cell DNA. Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of retroviruses, particularly HIV. The compounds of the invention comprise a (2,3?-dideoxy-?-ribofuranosyl) ring coupled to a heterocyclic nucleobase that lacks an “O2 carbonyl”, that enables them to selectively react with and inhibit viral reverse transcriptase, while remaining substantially unreactive toward human DNA polymerases.

Abstract: The present invention relates to dideoxynucleoside analog compounds containing a dideoxy ribofuranosyl moiety that exhibit selective anti-viral activity coupled with substantially low toxicity toward the host cells. In particular, the compounds according to the present invention show potent inhibition of the replication of the human immunodeficiency virus (HIV), while remaining substantially inert toward host cell DNA. Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of retroviruses, particularly HIV. The compounds of the invention comprise a (2,3 ′-dideoxy-&bgr;-ribofuranosyl) ring coupled to a heterocyclic nucleobase that lacks an “O2 carbonyl”, that enables them to selectively react with and inhibit viral reverse transcriptase, while remaining substantially unreactive toward human DNA polymerases.